TRAIL-R激动性抗体的临床研究进展  

Clinical research advance of TRAIL-R agonistic antibodies

作　　者：张妍[1] 陈曦[2] 彭永海[2] 欧阳学农[2] 

机构地区：[1]福建医科大学福州总医院临床医学院,350025 [2]南京军区福州总医院肿瘤科,福州350025

出　　处：《临床肿瘤学杂志》2014年第7期654-661,共8页Chinese Clinical Oncology

摘　　要：肿瘤坏死因子相关凋亡配体受体(TRAIL-R)是TRAIL介导细胞凋亡的重要结合靶点,其中TRAIL-R1和TRAIL-R2(即死亡受体4和死亡受体5)是与诱导细胞凋亡最直接相关的受体,也是最具有开发前景的药物设计靶点。本文对TRAIL-R及其抗体的临床前和临床研究作全面综述,为探索TRAIL介导的抗肿瘤治疗进一步研究提供参考。Tumor necrosis factor-related apoptosis-inducing ligand receptor（TRAIL-R）, one of important binding targets of TRAIL-mediated apoptosis, including TRAIL-R1 and TRAIL-R2（ ie, death receptor 4 and death receptor 5） not only directly relates to the induction of apoptosis receptors, but also one of the most promising targets for drug design. We carried out a comprehensive review of these antibodies？preclinical and clinical studies to explore the TRAIL-mediated anti-tumor therapy and provide references for further study.

关 键 词：肿瘤坏死因子相关凋亡配体受体 TRAIL-R1 TRAIL—R2 细胞凋亡 抗体 

分 类 号：R730[医药卫生—肿瘤]